Considering that around 40% of SLNB patients had HER2-enriched or triple negative breast cancer, these could be neoadjuvant patients for whom axillary surgery was de-escalated, however, their prognosis is completely different from patients undergoing upfront surgery. Here, ERBB2 is linked to triple-negative breast carcinoma.